Two other large studies involving breast cancer survivors who used tamoxifen (Abraham et al., 2010; Madlensky et al., 2011) also suggested the lack of association between CYP2D6 genotypes, or estimated CYP2D6 metabolizing phenotypes, and breast cancer outcomes. This evidence concerns the gene CYP2D6 and breast carcinoma.